We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $55.9 · 9 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
A filing was submitted.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Sanofi’s Venglustat Granted Priority Review By The FDA For Treatment Of GD3 (May 28) - TradingView
Sanofi’s Venglustat Granted Priority Review By The FDA For Treatment Of GD3 (May 28) TradingView
Andrea Michael Meyer, Sanofi: Collaboration is an Imperative - Supply Chain Digital
Andrea Michael Meyer, Sanofi: Collaboration is an Imperative Supply Chain Digital
FDA grants priority review for Sanofi’s venglustat NDA - Pharmaceutical Technology
FDA grants priority review for Sanofi’s venglustat NDA Pharmaceutical Technology
Sanofi Rare Disease Pipeline Progress Puts Recent Share Price Weakness In Focus - Yahoo Finance
Sanofi Rare Disease Pipeline Progress Puts Recent Share Price Weakness In Focus Yahoo Finance
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | After market close (AMC) | $1.13 | — | — | $11B | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 01. 16. | UBS | — | Downgrade | Buy → Neutral | — | UBS: Buy → Neutral |
| 2026. 01. 07. | Barclays | — | Downgrade | Overweight → Equal-Weight | — | Barclays: Overweight → Equal-Weight |
| 2025. 12. 09. | Guggenheim | — | Downgrade | Buy → Neutral | — | Guggenheim: Buy → Neutral |
| 2025. 12. 08. | JP Morgan | — | Downgrade | Overweight → Neutral | — | JP Morgan: Overweight → Neutral |
| 2025. 09. 08. | Morgan Stanley | — | Upgrade | Equal-Weight → Overweight | — | Morgan Stanley: Equal-Weight → Overweight |
| 2025. 09. 03. | Deutsche Bank | — | Upgrade | Hold → Buy | — | Deutsche Bank: Hold → Buy |
Price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 331,765 | $16.08B | 0.03% | — | New position |